BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 182 filers reported holding BRIDGEBIO PHARMA INC in Q1 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,270 | +390.3% | 86,071 | +208.4% | 0.19% | +321.7% |
| Q1 2023 | $463 | +61.9% | 27,908 | -25.6% | 0.05% | +31.4% |
| Q4 2022 | $286 | -99.9% | 37,501 | -14.2% | 0.04% | -39.7% |
| Q3 2022 | $434,000 | -54.6% | 43,691 | -58.5% | 0.06% | -59.4% |
| Q2 2022 | $955,000 | +169.0% | 105,177 | +200.4% | 0.14% | +197.9% |
| Q1 2022 | $355,000 | +53.0% | 35,013 | +152.1% | 0.05% | +65.5% |
| Q4 2021 | $232,000 | -94.8% | 13,889 | -85.5% | 0.03% | -93.7% |
| Q3 2021 | $4,499,000 | +555.8% | 95,996 | +753.5% | 0.46% | +494.8% |
| Q2 2021 | $686,000 | -7.0% | 11,247 | +8.3% | 0.08% | -36.4% |
| Q4 2020 | $738,000 | -75.4% | 10,385 | -87.0% | 0.12% | -75.8% |
| Q3 2020 | $2,997,000 | – | 79,890 | – | 0.50% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $100,609,513 | 48.41% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $514,990,899 | 15.50% |
| M28 Capital Management LP | 304,700 | $5,051,926 | 5.71% |
| Cormorant Asset Management, LP | 4,557,414 | $75,562 | 4.98% |
| Octagon Capital Advisors LP | 1,338,160 | $22,186,693 | 3.19% |
| Ikarian Capital, LLC | 594,686 | $9,859,894 | 2.24% |
| Affinity Asset Advisors, LLC | 389,800 | $6,462,884 | 2.13% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $441,376,031 | 2.07% |
| Ikarian Capital, LLC | 549,600 | $9,112,368 | 2.07% |
| Affinity Asset Advisors, LLC | 320,000 | $5,305,600 | 1.75% |